Therdose Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: Therdose Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 4 Products, $1.1M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Therdose Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 4 Products, $1.1M Trade | TransData Nexus

Therdose Pharma Private Limited

Indian Pharmaceutical Exporter · Oncology Specialist · $1.1M Total Trade · DGFT Verified

Therdose Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $1.1M across 4 products in 2 therapeutic categories. Based on 76 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Docetaxel ($490.0K), Carmustine ($455.2K), Irinotecan ($143.3K).

Therdose Pharma Private Limited — Export Portfolio & Destination Treemap

Therdose Pharma Private Limited pharmaceutical export portfolio — 4 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is Therdose Pharma Private Limited? — Company Overview & Market Position

Therdose Pharma Private Limited, established on December 19, 2003, is a Hyderabad-based pharmaceutical company specializing in oncology. The company operates under the Corporate Identification Number (CIN) U24239TG2003PTC042272 and is registered with the Registrar of Companies in Hyderabad, Telangana. Therdose Pharma is a private, non-government company with an authorized capital of ₹100 million and a paid-up capital of ₹99.906 million. The company's registered office is located at Plot No.118, 119 & 120, Survey No.342, Aleap Industrial Estate, Opposite JNTU, Pragati Nagar, Kukatpally, Hyderabad, Telangana, 500072, India. As of December 23, 2025, Therdose Pharma employed between 51 and 200 individuals. The company's official website is www.therdose.com.

What Does Therdose Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Docetaxel$490.0K 2Carmustine$455.2K

Product Portfolio — Top 4 by Export Value

Therdose Pharma Private Limited exports 4 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Docetaxel	Oncology	$490.0K	29	1.2%	14
2	Carmustine	Advanced Oncology	$455.2K	22	2.0%	4
3	Irinotecan	Oncology	$143.3K	21	0.3%	14
4	Pazopanib	Advanced Oncology	$27.9K	4	0.3%	9

Therdose Pharma Private Limited exports 4 pharmaceutical products across 2 therapeutic categories with a total export value of $1.1M. The top category is Oncology (56.7% of portfolio), followed by Advanced Oncology (43.3%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

Therdose Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

Therdose Pharma operates a manufacturing facility located in Hyderabad, Telangana, India. The plant specializes in the production of oncology-focused pharmaceutical formulations, including injectable and solid oral dosage forms. The facility is WHO GMP certified, ensuring compliance with international quality standards. Specific details regarding the plant's capacity and additional specializations are not publicly disclosed.

3Key Leadership

As of November 12, 2021, Ratna Sekhar Rao Imadabathuni serves as the Managing Director of Therdose Pharma Private Limited. Other key executives include Meka Kesava Sambasiva Rao (Director), Arvind Reddy Panyala (Director), Mahindra Dev Imadabathuni (Whole-Time Director), and Raja Vakula Devi Imadabathuni (Director). Narayana Raju Mantana was appointed as a Director on April 15, 2024. The company's leadership team comprises professionals with expertise in pharmaceutical manufacturing, regulatory affairs, and business development.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does Therdose Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

Therdose Pharma Private Limited has established a presence in several regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company's manufacturing facility holds WHO GMP certification, which is recognized by regulatory authorities in these regions. While specific details regarding regulatory filings, approvals, and market access status in these countries are not publicly disclosed, the WHO GMP certification indicates compliance with international quality standards, facilitating market entry.

2Emerging Markets

Therdose Pharma has expanded its reach into emerging markets across Africa, Latin America, and Southeast Asia. The company's WHO GMP certification supports its efforts to obtain product registrations in these regions. By filing over 40 dossiers across 25 emerging markets, Therdose Pharma demonstrates its commitment to providing oncology-focused pharmaceutical products globally.

3Geographic Strategy

Therdose Pharma's geographic strategy involves diversification into both regulated and emerging markets. The company's WHO GMP certification facilitates access to various international markets, reducing concentration risk. By filing product dossiers in multiple countries, Therdose Pharma aims to establish a global footprint in the oncology pharmaceutical sector.

Therdose Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

Specific details regarding Therdose Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's WHO GMP certification suggests adherence to international quality standards, which is a prerequisite for FDA approvals. However, without explicit information, a comprehensive assessment of the company's FDA status cannot be made.

2WHO & EU GMP

Therdose Pharma's manufacturing facility holds WHO GMP certification, indicating compliance with international quality standards. While the company has not publicly disclosed EU GMP certification, the WHO GMP certification is recognized by European regulatory authorities, facilitating market access. Specific details regarding the European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not available.

3CDSCO & Indian Regulatory

Therdose Pharma operates under the regulatory oversight of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is WHO GMP certified, which is recognized by Indian authorities. Specific details regarding state drug controller approvals and export No Objection Certificates (NOCs) are not publicly disclosed.

Therdose Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

In the oncology pharmaceutical sector, Therdose Pharma competes with other Indian manufacturers such as Cipla, Dr. Reddy's Laboratories, and Sun Pharmaceutical Industries. While specific market share data is not publicly available, Therdose Pharma's focus on oncology and its WHO GMP certification position it as a competitive player in this niche market.

2Key Differentiators

Therdose Pharma's key differentiators include its specialization in oncology, strong in-house research and development capabilities, and WHO GMP certified manufacturing facility. The company's focus on developing complex drug molecules and its commitment to regulatory compliance enable it to serve diverse pharmaceutical needs globally.

3Strategic Position

Therdose Pharma's current strategic direction centers on the development and manufacturing of oncology-focused pharmaceutical products, including generics and specialty drugs. The company's WHO GMP certification and global dossier filings indicate a strategic focus on expanding its international presence. Future outlooks suggest continued growth in emerging markets and potential expansion into additional regulated markets.

Buyer Due Diligence Brief — Evaluating Therdose Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

Therdose Pharma has demonstrated a consistent track record in the development and manufacturing of oncology pharmaceutical products. The company's export volume and consistency are supported by its WHO GMP certification and global dossier filings. Reliability indicators include adherence to international quality standards and a focus on regulatory compliance.

2Certifications to Verify

Importers should verify the following certifications when considering Therdose Pharma as a supplier:

WHO GMP Certification: Indicates compliance with international quality standards.

EU GMP Certification: Facilitates market access within the European Union.

FDA Approval: Necessary for market entry into the United States.

Frequently Asked Questions — Therdose Pharma Private Limited

How many pharmaceutical products does Therdose Pharma Private Limited export from India?

Therdose Pharma Private Limited exports 4 pharmaceutical products across 2 therapeutic categories. The top exports are Docetaxel ($490.0K), Carmustine ($455.2K), Irinotecan ($143.3K), Pazopanib ($27.9K). Total export value is $1.1M.

What is Therdose Pharma Private Limited's total pharmaceutical export value?

Therdose Pharma Private Limited's total pharmaceutical export value is $1.1M, based on 76 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does Therdose Pharma Private Limited cover?

Therdose Pharma Private Limited exports across 2 therapeutic categories. The largest are Oncology (56.7%, 2 products), Advanced Oncology (43.3%, 2 products).

Get Full Therdose Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. For current shipment-level data, contact TransData Nexus.